Aggensteiner, Pascal-M. http://orcid.org/0000-0002-1048-9044
Brandeis, D.
Millenet, S.
Hohmann, S.
Ruckes, C.
Beuth, S.
Albrecht, B.
Schmitt, G.
Schermuly, S.
Wörz, S.
Gevensleben, H.
Freitag, C. M.
Banaschewski, T.
Rothenberger, A.
Strehl, U.
Holtmann, M.
Funding for this research was provided by:
German Research Foundation (DFG HO 2503/4-1, DFG HO 2503/4-2)
Article History
Received: 4 October 2018
Accepted: 20 December 2018
First Online: 4 January 2019
Compliance with ethical standards
:
: AR is member of an advisory board and speakers’ bureau of Lilly, Shire, Medice and Novartis. He has received research and travel support and an educational grant from Shire. CF has received speaker’s fees from Eli Lilly and Shire. TB has served in an advisory or consultancy role for Hexal Pharma, Lilly, Medice, Novartis, Otsuka, Oxford Outcomes, PCM Scientific, Shire and Vifor Pharma. He has received conference attendance support and conference support or received speaker’s fees from Lilly, Medice, Novartis and Shire. He is/has been involved in clinical trials conducted by Lilly, Shire and Vifor Pharma. MH has served in an advisory or consultancy role for Medice and Shire, and has received conference attendance support or was paid for public speaking by Lilly, Medice, neuroConn and Shire. US has been paid for public speaking by neuroCare, the German Society for Biofeedback. DB serves as an unpaid scientific consultant of an EU-funded neurofeedback trial. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.